Review
Copyright ©2014 Baishideng Publishing Group Inc.
World J Gastroenterol. Oct 28, 2014; 20(40): 14821-14830
Published online Oct 28, 2014. doi: 10.3748/wjg.v20.i40.14821
Figure 1
Figure 1 Effects of glucagon-like peptide-1 receptor agonist on non-alcoholic fatty liver disease and inflammation. PPAR-α: Peroxisome proliferator-activated receptor; IHL: intrahepatic lipids; AMPK: AMP-activated protein kinase; CRP: C reactive protein; AGEs: Advanced glycation and end products; JNK: c-Jun NH2-terminal kinase; GLP-1RA: Glucagon-like peptide-1 receptor agonist; NAFLD: Non-alcoholic fatty liver disease.